CFDE Data Portal | Search GLIS3-AS1

	Label	Description
	GLIS3-AS1 associations Collection (Entity type)	Associations for GLIS3-AS1_associations
	GLIS3-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GLIS3-AS1 Gene (Entity type)	ENSG00000237009 - GLIS3 antisense RNA 1
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 0 V 3 TRAMETINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 7 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135030 3 V 10 FLUDARABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE109285 3 V 2 GLUCAGON MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE165334 2 V 0 DABRAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GLIS3-AS1 associations

Associations for GLIS3-AS1_associations

GLIS3-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

GLIS3-AS1

ENSG00000237009 - GLIS3 antisense RNA 1

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE197555 0 V 3 TRAMETINIB HUMAN UP

A Gene Set from LINCS

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 7 v 5 human dn

A Gene Set from LINCS

GSE135030 3 V 10 FLUDARABINE HUMAN UP

A Gene Set from LINCS

GSE109285 3 V 2 GLUCAGON MOUSE UP

A Gene Set from LINCS

GSE165334 2 V 0 DABRAFENIB HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.